Articles related to FDA

Did you know that recent court decisions could impact how we learn about drug risks? For instance, lecanemab (Leqembi), a new treatment for Alzheimer’s disease, has potential risks that are not fully disclosed in its label.

This recent development regarding survival rates in the study underscores the complexity and challenges in developing effective treatments for ALS.

Stay abreast of the latest developments in patient care. Learn more about the FDA’s recent warning on the potential risks associated with compounded ketamine products used for treating psychiatric disorders.

Stay informed about the latest research on factors influencing COVID-19 outcomes. Learn more about how these findings could influence your approach to patient care.

Stay informed about recent recalls to ensure patient safety. Learn more about the recall of a blood pressure medication contaminated with oxycodone.

The FDA’s recent approval of Pombiliti + Opfolda just expanded treatment options for the rare inherited lysosomal disorder.